Uncategorized

Hurt by a slowdown in procedures for its heart valve replacement devices, Edwards said it is working with hospitals to manage workflow challenges.

Affera combines mapping technology with a catheter capable of performing radiofrequency and pulsed field ablation.

Home health is already a lucrative market, and Providence expects demand for services to only grow as patients age, according to CFO Greg Hoffman.

Baxter still does not have a timeline for fully restoring production at the North Carolina facility, which was hit by Hurricane Helene.

Pfizer CEO Albert Bourla is in a tough spot as activist investor Starboard Value continues to call for a change in the company’s leadership. However, analysts are supportive of the embattled executive.

Analysts expect Kamala Harris to largely continue the current approach to AI oversight, while Donald Trump’s promise to repeal a Biden executive order signals a major shift.

The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, bringing in almost $700 million in the third quarter. Leerink Partners analyst David Risinger in a Friday note to investors said Sanofi expects Q4 Beyfortus sales similar to Q3.

MultiPlan, which denies the allegations, has been sued dozens of times over concerns the company is conspiring with health insurers to underpay doctors for out-of-network care.

En la vida moderna, mantener una concentración óptima y una alta productividad es un desafío constante, especialmente cuando las demandas laborales y personales son cada vez más exigentes. Un suplemento para memoria puede ser una herramienta efectiva para potenciar tus ca …

Bank of America analysts said prior to Thursday’s readout that Tyra Biosciences’ TYRA-300 could rival Johnson & Johnson’s kinase inhibitor Balversa, which has suffered from safety concerns and poor tolerability.